For the first time, researchers at Umeå University have demonstrated the full capabilities of their large-scale laser facility. In a study published in Nature Photonics, the team reports generating a combination of ultrashort laser pulses, extreme peak power, and precisely controlled waveforms that make it possible to explore the fastest processes in nature.
Hugh Rogers, CEO of BioNxt Solutions, commented: Our team is dedicated to advancing targeted chemotherapy delivery technology to help improve the standard of care for cancer patients.
We look forward to sharing further updates as the programme moves forward.
Unlike conventional chemotherapy, which circulates toxic agents system-wide, BioNxt’s proprietary targeted drug delivery system (TDDS) uses a dual-action mechanism that zeroes in on tumours while safeguarding healthy cells.
Once the drug reaches the tumour environment, it becomes activated and begins releasing its chemotherapeutic payload. Meanwhile, any drug molecules that stray beyond the tumour are rapidly neutralised, only to be reactivated if they re-enter the tumour zone.
BioNxt Solutions unveils a revolutionary chemotherapy delivery platform that targets tumours directly, boosting treatment effectiveness.
We analyse five potential trajectories for the development of quantum computing, based on current technical achievements and fundamental challenges. We draw from recent experimental results including Google’s Willow processor achieving below-threshold error correction. We also consider IBM’s quantum roadmap and emerging classical algorithms that challenge quantum supremacy. Additionally, our evaluation includes the bifurcation between NISQ and fault-tolerant approaches.